HCAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HCAT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has weak fundamental momentum, mixed-to-bearish analyst sentiment, insider selling, and no strong proprietary buy signal. Even though the pre-market move is positive, the current setup looks more like a speculative hold than a high-conviction long-term entry. My direct view: do not buy now; wait for clearer evidence of growth stabilization and execution improvement.
HCAT is trading pre-market at 1.33, up 6.40%, right at the pivot level of 1.33. RSI_6 at 41.35 is neutral and does not show strong bullish momentum. MACD histogram is slightly positive at 0.0255 but is positively contracting, which suggests momentum is not strengthening materially. Moving averages are converging, indicating a flat to uncertain trend rather than a confirmed uptrend. Key levels: support at 1.233 and 1.172, resistance at 1.427 and 1.488. Based on the pattern data, the stock has only modest near-term upside and a negative weekly bias.
Health Catalyst appointed Steve Nelson, EVP of Aetna, to its Board of Directors effective May 1, 2026, which may support its leadership transformation in healthcare. There is also some long-term narrative support from AI-focused investments and the need for application-layer healthcare data solutions, according to some analysts. Gross margin improved to 35.48% in the latest quarter, which is a constructive operational point.
Wells Fargo downgraded HCAT to Equal Weight and cut its price target from $5 to $1, citing persistent revenue and margin pressure into 2027 and no easy fix. Several other firms also cut targets in March, reflecting weaker expectations. Insiders are selling aggressively, with selling up 869.22% over the last month. Revenue fell 6.19% YoY in Q4, and FY26 guidance has been delayed while the company conducts a strategic review. There is no recent congress trading data and no strong event-driven insider or political support.
In 2025/Q4, Health Catalyst showed weaker top-line performance with revenue down 6.19% YoY to 74.68M. Profitability remains deeply negative, with net income at -91.03M and EPS at -1.28, although both losses improved year over year. Gross margin improved to 35.48%, up 15.42% YoY, which is a positive sign, but the company is still not demonstrating durable earnings power. For a long-term beginner investor, the latest quarter does not yet show a clean turnaround.
Analyst sentiment has turned cautious to negative. Wells Fargo downgraded the stock to Equal Weight and slashed its target to $1. Stephens, Citi, and Stifel also lowered targets and stayed Neutral/Equal Weight/Hold, while Canaccord and Cantor remained more constructive but still reduced targets substantially. The overall Wall Street view is cautious: pros see optionality from leadership change, AI investment, and strategic review, while cons focus on revenue decline, margin pressure, delayed guidance, and possible customer attrition. Net takeaway: analyst tone is bearish-to-neutral rather than supportive.
